Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma.
Rapposelli IG, Shimose S, Kumada T, Okamura S, Hiraoka A, Di Costanzo GG, Marra F, Tamburini E, Forgione A, Foschi FG, Silletta M, Lonardi S, Masi G, Scartozzi M, Nakano M, Shibata H, Kawata K, Pellino A, Vivaldi C, Lai E, Takata A, Tajiri K, Toyoda H, Tortora R, Campani C, Viola MG, Piscaglia F, Conti F, Fulgenzi CAM, Frassineti GL, Rizzato MD, Salani F, Astara G, Torimura T, Atsukawa M, Tada T, Burgio V, Rimini M, Cascinu S, Casadei-Gardini A. Rapposelli IG, et al. Among authors: silletta m. ESMO Open. 2021 Aug;6(4):100190. doi: 10.1016/j.esmoop.2021.100190. Epub 2021 Jun 16. ESMO Open. 2021. PMID: 34144271 Free PMC article.
Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.
Vincenzi B, Di Maio M, Silletta M, D'Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G. Vincenzi B, et al. Among authors: silletta m. PLoS One. 2015 Jul 31;10(7):e0133488. doi: 10.1371/journal.pone.0133488. eCollection 2015. PLoS One. 2015. PMID: 26230853 Free PMC article.
Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review.
Casadei Gardini A, Santini D, Aprile G, Silvestris N, Felli E, Foschi FG, Ercolani G, Marisi G, Valgiusti M, Passardi A, Puzzoni M, Silletta M, Brunetti O, Cardellino GG, Frassineti GL, Scartozzi M. Casadei Gardini A, et al. Among authors: silletta m. Oncotarget. 2017 Jul 22;8(39):66699-66708. doi: 10.18632/oncotarget.19449. eCollection 2017 Sep 12. Oncotarget. 2017. PMID: 29029548 Free PMC article. Review.
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.
Gardini AC, Faloppi L, Aprile G, Brunetti O, Caparello C, Corbelli J, Chessa L, Bruno D, Ercolani G, Leonetti A, Stefano G, Farella N, Foschi FG, Lanzi A, Dadduzio V, Marisi G, Masi G, Negri FV, Pagan F, Santini D, Scarpi E, Silletta M, Silvestris N, Tamburini E, Tassinari D, Vivaldi C, Gentilucci UV, Zagonel V, Calvetti L, Cascinu S, Frassineti GL, Scartozzi M. Gardini AC, et al. Among authors: silletta m. Tumori. 2018 Dec;104(6):476-479. doi: 10.5301/tj.5000704. Epub 2018 May 9. Tumori. 2018. PMID: 29739298 Free article.
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study.
Casadei-Gardini A, Marisi G, Dadduzio V, Gramantieri L, Faloppi L, Ulivi P, Foschi FG, Tamburini E, Vivaldi C, Rizzato MD, Ielasi L, Canale M, Conti F, Rudnas B, Fornaro L, Silvestris N, Silletta M, Cardellino GG, Lonardi S, Fornari F, Orsi G, Rovesti G, Zagonel V, Cascinu S, Scartozzi M. Casadei-Gardini A, et al. Among authors: silletta m. Clin Cancer Res. 2020 Sep 1;26(17):4485-4493. doi: 10.1158/1078-0432.CCR-19-3897. Epub 2020 May 5. Clin Cancer Res. 2020. PMID: 32371540
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib.
Caputo F, Dadduzio V, Tovoli F, Bertolini G, Cabibbo G, Cerma K, Vivaldi C, Faloppi L, Rizzato MD, Piscaglia F, Celsa C, Fornaro L, Marisi G, Conti F, Silvestris N, Silletta M, Lonardi S, Granito A, Stornello C, Massa V, Astara G, Delcuratolo S, Cascinu S, Scartozzi M, Casadei-Gardini A. Caputo F, et al. Among authors: silletta m. PLoS One. 2020 May 7;15(5):e0232449. doi: 10.1371/journal.pone.0232449. eCollection 2020. PLoS One. 2020. PMID: 32379785 Free PMC article.
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
Rapposelli IG, Tada T, Shimose S, Burgio V, Kumada T, Iwamoto H, Hiraoka A, Niizeki T, Atsukawa M, Koga H, Hirooka M, Torimura T, Iavarone M, Tortora R, Campani C, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Giuseppe Foschi F, Silletta M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Tanaka T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Rimini M, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Rapposelli IG, et al. Among authors: silletta m. Liver Int. 2021 Dec;41(12):2997-3008. doi: 10.1111/liv.15014. Epub 2021 Jul 22. Liver Int. 2021. PMID: 34250737
Immunotherapy in Hepatocellular Carcinoma.
Fulgenzi CAM, Talbot T, Murray SM, Silletta M, Vincenzi B, Cortellini A, Pinato DJ. Fulgenzi CAM, et al. Among authors: silletta m. Curr Treat Options Oncol. 2021 Aug 23;22(10):87. doi: 10.1007/s11864-021-00886-5. Curr Treat Options Oncol. 2021. PMID: 34424422 Free PMC article. Review.
89 results